[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365-370.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
　Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(06):365-370.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
点击复制

替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年06期
页码:
365-370
栏目:
论著
出版日期:
2014-12-20

文章信息/Info

Title:
Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats
作者:
赵紫琴; 雒瑢; 田凤石; 郑喜兰
300211 天津医院病理科(赵紫琴); 300222 天津市胸科医院(雒瑢); 300140天津市第四中心医院心血管科(田凤石); 300350 天津市海河医院心血管科(郑喜兰)
Author(s):
Zhao Ziqin*;  Luo Rong;  Tian Fengshi;  Zheng Xilan.
*Department of Pathology, Tianjin Hospital, Tianjin 300210,ChinaCorresponding author: Tian Fengshi, Email: fengshitian0801@hotmail.com
关键词:
替米沙坦;  2型糖尿病;  过氧化物酶体增殖物活化受体γ;  脂肪组织
Keywords:
Telmisartan;  Type 2 diabetes mellitus;  Peroxisome proliferator-activatedreceptor γ;  Adipose tissue
DOI:
10.3760/cma.j.issn.1673-4157.2014.06.002
摘要:
目的 探讨替米沙坦对高脂饲养的OLETF大鼠皮下、内脏脂肪组织中过氧化物酶体增殖物活化受体(PPAR)γ1、PPARγ2基因表达的调控作用及其部位差异性。方法 4周龄雄性OLETF大鼠30只,性别、周龄匹配的正常非糖尿病LETO大鼠12只作为对照,OLETF大鼠从8周龄开始给予高脂喂养,22周龄时,口服葡萄糖耐量试验(OGTT)未发生临床糖尿病或糖耐量减低。之后将这些糖尿病前期OLETF大鼠按照随机数字表法分为替米沙坦干预组(O-T组,5 mg·kg-1·d-1,n=10)、吡格列酮干预组(O-P组,10 mg·kg-1·d-1,n=8)和无干预对照组(O-C组,生理盐水,n=10),LETO大鼠为对照组(n=12)。48周龄时,复查OGTT,计算稳态模型评估-胰岛素抵抗指数(HOMA-IR)。ELISA法测定血清PPARγ的水平,实时 PCR检测皮下和睾周脂肪组织中PPARγ1和PPARγ2的基因表达,并测定各组脂肪细胞的面积。结果 与O-C组相比,O-T组皮下脂肪中PPARγ2的表达明显升高(P<0.01),且O-T组与O-P组之间差异无统计学意义。O-T组内脏脂肪组织中PPARγ1和 PPARγ2的表达也明显上调(P<0.01),HOMA-IR与内脏脂肪组织中PPARγ2的mRNA表达水平呈负相关(ρ=-0.369,P=0.021)。与O-C组相比,O-T组脂肪细胞面积减少56%(P<0.01)。结论 替米沙坦可部分激活PPARγ,上调皮下及内脏脂肪组织中PPARγ1和PPARγ2的表达,减小脂肪细胞面积,增加胰岛素敏感性。
Abstract:
Objective To explore the regulation of telmisartan on expression of peroxisome proliferator-activated receptor(PPAR)γ1 and PPARγ2 in subcutaneous adipose tissue(SAT)and visceral adipose tissue(VAT)in high-fat diet fed OLETF rats and their tissue difference. Methods Thirty four-week-old male OLETF rats were selected and 12 gender-and age-matched Long-Evans Tokushima Otsuka(LETO)rats were used as normal control. From 8 weeks of age, the OLETF rats were fed with high-fat diet. At 22 weeks of age, there was no case of impaired glucose tolerance or type 2 diabetes mellitus in OLETF rats tested by oral glucose tolerance test(OGTT). Then, these pre-diabetic OLETF rats were divided into telmisartan group(O-T group, 5 mg·kg-1·d-1,n=10), pioglitazone group(O-P group, 10 mg·kg-1·d-1,n=8), and untreated control group(O-T group, n=10)according to the radom number table. LETO(n=12)rats were used as control group. OGTT was carried out at 48 weeks of age, and homeostasis model assessment of insulin resistance(HOMA-IR)was evaluated. Serum PPARγ was measured using ELISA. The mRNA levels of PPARγ1 and PPARγ2 in different fatty tissues were determined by real-time PCR. The adipocyte sizes were also assessed. Results Compared with O-C group, the PPARγ2 level in SAT was significantly up-regulated in O-Tgroup(P<0.01),while no difference was observed between O-T and O-P group. In addition, both PPARγ1 and PPARγ2 mRNA levels in VAT were up-regulated in O-T group(P<0.01). There was a negative correlation between HOMA-IR and PPARγ2 mRNA expression in VAT(ρ=-0.369,P=0.021). Compared with O-C group, the adipose cell size was decreased by 56% in O-T group. Conclusion Telmisartan can at least partially up-regulate the expression of PPARγ1 and PPARγ2 in SAT and VAT, decrease the adipose cell size, and improve insulin sensitivity by activating PPARγ.

参考文献/References:

[1] Ruiz J.The DREAM of diabetes prevention[J].Rev Med Suisse,2007,3(94):132,134-136.
[2] Kawano K,Hirashima T,Mori S, et al.Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty(OLETF)strain[J].Diabetes,1992,41(11):1422-1428.
[3] Braissant O,Foufelle F,Scotto C, et al.Differential expression of peroxisome proliferator-activated receptors(PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat[J].Endocrinology,1996,137(1):354-366.
[4] Okin PM,Devereux RB,Harris KE, et al. LIFE Study Investigators.In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients:the Losartan Intervention for Endpoint Reduction in Hypertension(LIFE)Study[J].Hypertension,2007,50(5):984-990.
[5] Aksnes TA,Kjeldsen SE,Rostrup M, et al.Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation(VALUE)trial population[J].Hypertension,2007,50(3):467-473.
[6] Macdonald MR,Petrie MC,Varyani F, et al.Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity(CHARM)programme[J].Eur Heart J,2008,29(11):1377-1385.
[7] Furukawa H,Mawatari K,Koyama K, et al.Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes[J].Eur J Pharmacol,2011,660(2/3):485-491.
[8] Schupp M,Janke J,Clasen R,et al.Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity[J].Circulation,2004,109(17):2054-2057.
[9] Chen X,Hess S.Adipose proteome analysis: focus on mediators of insulin resistance[J].Expert Rev Proteomics,2008,5(6):827-839.
[10] Drolet R,Richard C,Sniderman AD, et al.Hypertrophy and hyperplasia of abdominal adipose tissues in women[J].Int J Obes(Lond),2008,32(2):283-291.
[11] Sopasakis VR,Sandqvist M,Gustafson B,et al.High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator[J].Obes Res,2004,12(3):454-460.
[12] Perrini S,Ficarella R,Picardi E, et al.Differences in gene expression and cytokine release profiles highlight the heterogeneity of distinct subsets of adipose tissue-derived stem cells in the subcutaneous and visceral adipose tissue in humans[J].PLoS One,2013,8(3):e57892.
[13] 雒瑢.赵紫琴,田凤石,等.替米沙坦上调内脏脂肪组织的脂联素表达并改善胰岛素抵抗[J].中华糖尿病杂志,2013,5(7):418-424.
[14] Iwaki M, Matsuda M, Maeda N, et al.Intuction of adiponectina fat-derived antidiabetic and antiatherogenie factor,by nuclear receptiors[J].Diabetes,2003,52(6):1655-1663.
[15] Spencer M,Yang L,Adu A, et al.Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity[J].PLoS One,2014,9(7):e102190.
[16] Macias-Gonzalez M,Moreno-Santos I,García-Almeida JM, et al.PPARgamma2 protects against obesity by means of a mechanism that mediates insulin resistance[J].Eur J Clin Invest,2009,39(11):972-979.
[17] Matsumura T,Kinoshita H,Ishii N,et al.Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages[J].Arterioscler Thromb Vasc Biol,2011,31(6):1268-1275.
[18] Fujisaka S,Usui I,Kanatani Y, et al.Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice[J].Endocrinology,2011,152(5):1789-1799.

相似文献/References:

[1]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
　Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[2]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
　Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[3]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
　Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(06):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[4]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
　Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[5]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性 血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
　Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(06):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[6]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白 与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
　Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[7]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平 及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
　Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(06):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[8]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
　Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(06):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[9]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病 患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
　Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
[10]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
　Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(06):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]

更新日期/Last Update: 2014-12-20